NASDAQ$COCP
Cocrystal Pharma Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported financial results for Q2 2023 and provided updates on its antiviral drug development programs.
Cocrystal Pharma reported a net loss of $4.2 million, or $0.41 per share, for the second quarter of 2023. The company's cash position is sufficient to fund planned operations for the next 12 months.
- Advanced novel oral PB2 inhibitor CC-42344 for influenza A, submitting an application for UK MHRA approval to begin a Phase 2a human challenge trial.
- Received approval from the Australian regulatory agency to begin a first-in-human trial with novel, broad-spectrum oral protease inhibitor CDI-988 for COVID-19.
- Selected CDI-988 as the lead oral norovirus candidate.
- Expect to report top-line data of CDI-988 Phase 1 study in 2024.
Headline financials
Revenue & EPS history
Cocrystal Pharma · Revenue · Quarterly
$225K
Forward guidance
Cocrystal Pharma believes its current cash position is sufficient to fund planned operations for the next 12 months.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2023
-0.9%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+1.4%
Avg return
30 days after
33%
19 / 58 earnings
Positive
+25.0%
Q3 2024
Best reaction
-33.3%
Q1 2013
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.6% | -11.9% | — | |
| Q4 2026 | -2.9% | +51.0% | +43.0% | |
| Q3 2025 | +0.0% | -3.9% | +1.9% | |
| Q2 2025 | -1.2% | -8.9% | -6.0% | |
| Q1 2025 | -7.4% | +4.1% | +5.5% | |
| Q4 2024 | +4.1% | +6.5% | +23.6% | |
| Q3 2024 | +25.0% | +17.6% | +8.5% | |
| Q2 2024 | -10.0% | +10.5% | -12.1% | |
| Q1 2024 | +8.1% | +12.7% | +61.8% | |
| Q4 2023 | +0.0% | -1.3% | +4.0% | |
| Q3 2023 | -1.1% | -11.1% | -5.3% | |
| Q2 2023 | +2.1% | -5.9% | -31.1% | |
| Q1 2023 | -3.8% | -13.2% | -3.8% | |
| Q4 2022 | +4.4% | +8.3% | +37.8% | |
| Q3 2022 | +0.0% | -3.3% | -19.5% | |
| Q2 2022 | +0.0% | -8.7% | -23.9% | |
| Q1 2022 | -5.0% | +0.0% | +2.5% | |
| Q4 2021 | +1.7% | -1.7% | -12.1% | |
| Q3 2021 | -2.2% | -9.9% | -22.0% | |
| Q2 2021 | +2.9% | -1.0% | +2.9% | |
| Q1 2021 | +2.7% | +1.8% | +15.0% | |
| Q4 2020 | -5.0% | -2.5% | -24.5% | |
| Q3 2020 | -2.3% | +2.3% | +64.4% | |
| Q2 2020 | -7.3% | -10.5% | -58.6% | |
| Q1 2020 | -2.8% | -1.4% | +30.6% | |
| Q4 2019 | +5.9% | +2.9% | +33.8% | |
| Q3 2019 | -21.0% | -30.6% | -25.8% | |
| Q2 2019 | -10.8% | -14.9% | -34.0% | |
| Q1 2019 | +0.7% | -1.1% | -5.5% | |
| Q4 2018 | +0.7% | -1.1% | -5.5% | |
| Q3 2018 | +6.8% | +42.2% | +91.7% | |
| Q2 2018 | -5.5% | -4.3% | -19.4% | |
| Q1 2018 | +5.0% | -14.5% | -64.4% | |
| Q4 2017 | -2.1% | +10.9% | -30.0% | |
| Q4 2016 | +0.0% | +0.0% | -11.5% | |
| Q3 2017 | +0.0% | +0.0% | -11.5% | |
| Q2 2017 | +0.0% | +0.0% | +52.6% | |
| Q1 2017 | +0.0% | +15.4% | +3.8% | |
| Q3 2016 | +0.0% | -8.2% | -12.2% | |
| Q2 2016 | +4.4% | +0.0% | +11.1% | |
| Q4 2015 | -3.1% | — | — | |
| Q1 2016 | +7.0% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | +16.7% | — | — | |
| Q4 2014 | +16.7% | — | — | |
| Q3 2014 | +0.0% | — | — | |
| Q2 2014 | +12.1% | — | — | |
| Q1 2014 | +12.1% | — | — | |
| Q4 2013 | -3.3% | — | — | |
| Q3 2013 | -21.1% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q4 2012 | -33.3% | — | — | |
| Q1 2013 | -33.3% | — | — | |
| Q3 2012 | +0.0% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro